We are live on ! Find out more
PTGX icon

Protagonist Therapeutics

130 hedge funds and large institutions have $398M invested in Protagonist Therapeutics in 2022 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 40 increasing their positions, 40 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

717% more call options, than puts

Call options by funds: $7.01M | Put options by funds: $858K

0% more funds holding

Funds holding: 130 → 130 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 29

0% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 40

13.45% less ownership

Funds ownership: 109.63% → 96.17% (-13%)

49% less capital inflows, than outflows

Capital inflows: $52.9M | Capital outflows: $104M

Holders
130
Holders Change
–
Holders Change %
0%
% of All Funds
2.23%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
29
Increased
40
Reduced
40
Closed
29
Calls
$7.01​M
Puts
$858​K
Net Calls
+$6.16​M
Net Calls Change
-⁠$7.64​M

PTGX Hedge Fund Activity: Q3 2022 in Review

130 of the 5,834 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q3 2022, worth a combined $398M — down 5.7% from $422M a quarter earlier.

Fund positioning in PTGX was balanced in Q3 2022: 29 funds opened new positions, 29 closed out, 40 added to existing stakes and 40 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $7.5M. The largest seller was State Street, cutting an estimated $19.9M.

  • 130 institutional investors held Protagonist Therapeutics (PTGX) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $398M of Protagonist Therapeutics stock for Q3 2022, down 5.7% quarter-over-quarter.
  • 29 funds opened new Protagonist Therapeutics positions in Q3 2022 and 29 closed out, a net change of 0 holders.
  • The largest Protagonist Therapeutics buyer in Q3 2022 was Citadel Advisors, an estimated $7.5M added.
  • The largest Protagonist Therapeutics seller in Q3 2022 was State Street, an estimated $19.9M sold.

Based on aggregated 13F filings for Q3 2022.